(Q37620345)

21 August 2017

1 reference

title

Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer (English)

1 reference

21 August 2017

1 reference

2

Lesley J Scott

1 reference

21 August 2017

Mark Sanford

1

1 reference

21 August 2017

language of work or name

1 reference

1 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

69

1 reference

21 August 2017

issue

16

1 reference

21 August 2017

page(s)

2303-2328

1 reference

A translational view of the molecular pathogenesis of lung cancer

21 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F10489100-000000000-00000

Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

21 January 2018

1 reference

12 December 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

12 December 2020

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

1 reference

12 December 2020

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking

1 reference

12 December 2020

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study

1 reference

12 December 2020

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

Targeting the epidermal growth factor receptor in non-small cell lung cancer.

1 reference

12 December 2020

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

1 reference

12 December 2020

1 reference

12 December 2020

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

1 reference

12 December 2020

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

12 December 2020

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

1 reference

12 December 2020

Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

1 reference

12 December 2020

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

1 reference

12 December 2020

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

12 December 2020

Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group

1 reference

12 December 2020

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

1 reference

12 December 2020

Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.

1 reference

12 December 2020

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

1 reference

12 December 2020

Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

12 December 2020

Revisions in the International System for Staging Lung Cancer

1 reference

12 December 2020

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

1 reference

12 December 2020

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

12 December 2020

Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer

1 reference

12 December 2020

Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline

1 reference

12 December 2020

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

1 reference

12 December 2020

Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition).

1 reference

12 December 2020

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

1 reference

12 December 2020

Single-dose clinical pharmacokinetic studies of gefitinib

1 reference

12 December 2020

Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer

1 reference

12 December 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

12 December 2020

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

12 December 2020

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

1 reference

12 December 2020

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

1 reference

12 December 2020

Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

1 reference

12 December 2020

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study

1 reference

12 December 2020

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics

1 reference

12 December 2020

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

12 December 2020

10.2165/10489100-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

1014147245

0 references

1 reference